Seemingly irrational valuations, like SpaceX's, aren't just market froth. They are a necessary mechanism to fund ambitious, high-risk, capital-intensive projects like space data centers and satellite internet that would otherwise struggle to secure traditional funding.

Blue Origin's first outside funding round values it at $130 billion. This isn't based on traditional metrics like revenue but on its rare achievement of creating a reusable orbital rocket, a capability only SpaceX previously mastered, justifying a premium valuation.

Despite both companies having 'moonshot' ambitions, the market values them very differently. SpaceX trades at over 100 times its projected 2025 revenue, while Tesla is at a more modest 14 times. This disparity indicates the hype and long-term vision premium associated with Elon Musk is currently far more priced into SpaceX.

Many publicly traded space companies see soaring valuations disconnected from their financial reality. AST Space Mobile, for example, is valued at $30 billion despite having no commercial service and low actual revenue, fueled by hype and its positioning as a Starlink competitor.

A catastrophic rocket failure is more damaging for a pure-play launch company like Blue Origin. Competitor SpaceX mitigates this risk with diversified revenue streams from Starlink and AI, making its overall business more resilient to setbacks in any single division.

Investor Bill Ackman frames SpaceX's massive valuation not by traditional measures, but as a venture bet. Its value lies in the long-term, high-risk potential of its future businesses like global communications (Starlink), space-based computing, and energy, rather than its current financials.

The defensible case for SpaceX's massive valuation is less about Elon Musk's futuristic vision and more about its tangible competitive moat. The company has a functional monopoly on launch capabilities and a decade-long head start on its satellite internet business, controlling essential infrastructure for the future space economy.

Traditional analysis 'weighs' current performance (revenue, earnings). For disruptive companies, however, investors are often 'voting' on a future vision, a mindset more akin to venture capital. Understanding this duality is key to valuing moonshot stocks and explaining the disconnect between valuation and current financials.

Companies with long-term, capital-intensive goals and no immediate path to profitability are being valued like biotech firms. Both public and private markets are willing to fund these "moonshots" for years before revenue materializes, a model familiar in drug development but novel for mainstream tech.